Update MRONJ and perspectives of its treatment - 07/09/17
pages | 4 |
Iconographies | 4 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Antiresorptive agents are widely used in catabolic bone diseases. Not only bisphosphonates but also new drugs like Denosumab may induce osteonecrosis of the jaw as a side effect. The present review describes the current effect mechanisms of commonly used antiresorptives, pathogenetic theories for the development of antiresorptive-related osteonecrosis of the jaw (ARONJ), and potential risk factors. Furthermore, diagnostic modalities and treatment options as well as new and innovative strategies are discussed. The major key factor to avoid the occurrence of ARONJ still remains the implementation of throughout preventive measures.
Le texte complet de cet article est disponible en PDF.Keywords : Bisphosphonates, Osteonecrosis of the jaw, Denosumab, ARONJ
Plan
☆ | Article reported from the 53rd SFSCMFCO Congress (Marseille, October 4–7, 2017) and published under the responsibility of the Scientific Committee of the congress. |
Vol 118 - N° 4
P. 232-235 - septembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?